U A Matulonis1, R Shapira-Frommer2, A D Santin3, A S Lisyanskaya4, S Pignata5, I Vergote6, F Raspagliesi7, G S Sonke8, M Birrer9, D M Provencher10, J Sehouli11, N Colombo12, A González-Martín13, A Oaknin14, P B Ottevanger15, V Rudaitis16, K Katchar17, H Wu18, S Keefe19, J Ruman19, J A Ledermann20. 1. Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, USA. Electronic address: Ursula_Matulonis@dfci.harvard.edu. 2. Oncology Institute and Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel. 3. Obstetrics, Gynecology & Reproductive Sciences, Yale University School of Medicine, New Haven, USA. 4. Department of Gynaecological Oncology, City Clinical Oncology Dispensary, Saint Petersburg, Russia. 5. Department of Urogynaecological Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione G Pascale", IRCCS, Naples, Italy. 6. Department of Obstetrics and Gynaecology and Gynaecologic Oncology, University Hospital Leuven, Leuven, Belgium. 7. Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy. 8. Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. 9. Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, USA. 10. Hôpital Notre-Dame - Pavillon L-C Simard, Centre Hospitalier de L'Université de Montréal (CHUM), Montreal, Canada. 11. Gynecology and Obstetrics, Charité-Medical University of Berlin, Berlin, Germany. 12. Department of Surgical Sciences, University of Milano-Bicocca and European Institute of Oncology, Milano, Italy. 13. Medical Oncology, Clinica Universidad de Navarra; formerly of MD Anderson International España, Madrid. 14. Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. 15. Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands. 16. Clinic of Obstetrics and Gynecology, Vilnius University Institute of Clinical Medicine, Vilnius, Lithuania. 17. Companion Diagnostics, Merck & Co., Inc, Kenilworth, USA. 18. BARDS, MSD China, Beijing, China. 19. Clinical Development, Merck & Co., Inc., Kenilworth, USA. 20. UCL Cancer Institute and UCL Hospitals, Department of Oncology, University College London, London, UK.
Abstract
BACKGROUND: Advanced recurrent ovarian cancer (ROC) is the leading cause of gynecologic cancer-related death in developed countries and new treatments are needed. Previous studies of immune checkpoint blockade showed low objective response rates (ORR) in ROC with no identified predictive biomarker. PATIENTS AND METHODS: This phase II study of pembrolizumab (NCT02674061) examined two patient cohorts with ROC: cohort A received one to three prior lines of treatment with a platinum-free interval (PFI) or treatment-free interval (TFI) between 3 and 12 months and cohort B received four to six prior lines with a PFI/TFI of ≥3 months. Pembrolizumab 200 mg was administered intravenously every 3 weeks until cancer progression, toxicity, or completion of 2 years. Primary end points were ORR by Response Evaluation Criteria in Solid Tumors version 1.1 per blinded independent central review by cohort and by PD-L1 expression measured as combined positive score (CPS). Secondary end points included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: Cohort A enrolled 285 patients; the first 100 served as the training set for PD-L1 biomarker analysis. Cohort B enrolled 91 patients. ORR was 7.4% for cohort A and 9.9% for cohort B. Median DOR was 8.2 months for cohort A and not reached for cohort B. DCR was 37.2% and 37.4%, respectively, in cohorts A and B. Based on the training set analysis, CPS 1 and 10 were selected for evaluation in the confirmation set. In the confirmation set, ORR was 4.1% for CPS <1, 5.7% CPS ≥1, and 10.0% for CPS ≥10. PFS was 2.1 months for both cohorts. Median OS was not reached for cohort A and was 17.6 months for cohort B. Toxicities were consistent with other single-agent pembrolizumab trials. CONCLUSIONS: Single-agent pembrolizumab showed modest activity in patients with ROC. Higher PD-L1 expression was correlated with higher response. CLINICAL TRIAL NUMBER: Clinicaltrials.gov, NCT02674061.
BACKGROUND: Advanced recurrent ovarian cancer (ROC) is the leading cause of gynecologic cancer-related death in developed countries and new treatments are needed. Previous studies of immune checkpoint blockade showed low objective response rates (ORR) in ROC with no identified predictive biomarker. PATIENTS AND METHODS: This phase II study of pembrolizumab (NCT02674061) examined two patient cohorts with ROC: cohort A received one to three prior lines of treatment with a platinum-free interval (PFI) or treatment-free interval (TFI) between 3 and 12 months and cohort B received four to six prior lines with a PFI/TFI of ≥3 months. Pembrolizumab 200 mg was administered intravenously every 3 weeks until cancer progression, toxicity, or completion of 2 years. Primary end points were ORR by Response Evaluation Criteria in Solid Tumors version 1.1 per blinded independent central review by cohort and by PD-L1 expression measured as combined positive score (CPS). Secondary end points included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: Cohort A enrolled 285 patients; the first 100 served as the training set for PD-L1 biomarker analysis. Cohort B enrolled 91 patients. ORR was 7.4% for cohort A and 9.9% for cohort B. Median DOR was 8.2 months for cohort A and not reached for cohort B. DCR was 37.2% and 37.4%, respectively, in cohorts A and B. Based on the training set analysis, CPS 1 and 10 were selected for evaluation in the confirmation set. In the confirmation set, ORR was 4.1% for CPS <1, 5.7% CPS ≥1, and 10.0% for CPS ≥10. PFS was 2.1 months for both cohorts. Median OS was not reached for cohort A and was 17.6 months for cohort B. Toxicities were consistent with other single-agent pembrolizumab trials. CONCLUSIONS: Single-agent pembrolizumab showed modest activity in patients with ROC. Higher PD-L1 expression was correlated with higher response. CLINICAL TRIAL NUMBER: Clinicaltrials.gov, NCT02674061.
Authors: Dmitriy Zamarin; Robert A Burger; Michael W Sill; Daniel J Powell; Heather A Lankes; Michael D Feldman; Oliver Zivanovic; Camille Gunderson; Emily Ko; Cara Mathews; Sudarshan Sharma; Andrea R Hagemann; Samir Khleif; Carol Aghajanian Journal: J Clin Oncol Date: 2020-04-10 Impact factor: 44.544
Authors: Julia L Boland; Qin Zhou; Alexia E Iasonos; Roisin E O'Cearbhaill; Jason Konner; Margaret Callahan; Claire Friedman; Carol Aghajanian; Paul Sabbatini; Dmitriy Zamarin; Karen A Cadoo Journal: Gynecol Oncol Date: 2020-06-02 Impact factor: 5.482
Authors: Kathryn M Appleton; Ashley K Elrod; Katy A Lassahn; Stephen Shuford; Lillia M Holmes; Teresa M DesRochers Journal: Cancer Immunol Immunother Date: 2021-01-25 Impact factor: 6.968
Authors: Ying L Liu; Pier Selenica; Qin Zhou; Alexia Iasonos; Margaret Callahan; Noah Z Feit; Julia Boland; Ignacio Vazquez-Garcia; Diana Mandelker; Ahmet Zehir; Robert A Burger; Daniel J Powell; Claire Friedman; Karen Cadoo; Rachel Grisham; Jason A Konner; Roisin E O'Cearbhaill; Carol Aghajanian; Jorge S Reis-Filho; Britta Weigelt; Dmitriy Zamarin Journal: JCO Precis Oncol Date: 2020-06-16